Published Standard Number 1 – Applications (National)

Application number	Application type	Number of applications	Performance	Target days	Average days
1	Major timetable (National) New MRLs. All other MA applications (excl. MAPI and Copycats)	0	100%	180.0	0
2	Standard timetable (National Type II variations. New MA - MAPIs and Copycats. New VHRs)	5	100%	120.0	15
3	Shortened timetable (National Renewals (MA and VHR) Type IB variations. New ATC (type B). Out of Scope MRLs)	40	100%	60.0	16
4	Minor timetable (National) Type IA variations. Administrative Type IB variations. New ATC (Type A/S). ATC variations and renewals.	114	96.5%	30.0	24
5	Parallel Assessment with EU Procedures	63	100%	-	14
6	Shared Assessment with International Partners	0	-	-	0
7	Batch timetable (National) specific Batch Control	7	100%	20.0	0
8	Autogenous Vaccines. New & Variations	0	0	45.0	0

Published Standard Number 1 – Applications (Other)

Application number	Application Type	Number of applications	Performance
9	Mock-up period completed within 20 days (or up to 40 days for parallel applications involving different QRD sources)	69	98.6%
10	Validation	121	100%
11	Issue of authorised documentation	199	100%

Published Standard Number 1 – Applications (European - NI)

Application number	Application Type	Number of applications	Performance
12	New Decentralised (DCP)	2	100%
13	New Mutual Recognition (MRP)	0	0
14	MRP Variations (Type IB & II) and Renewals	8	100%

Published Standard Number 2 – Public Assessment Reports

Application number	Application type	Total number	Performance
15	Publishing Summary of Product Characteristics (SPCs)	1	100%
16	Publishing Public Assessment Reports (PuARs)	1	100%
17	Updating PuARs	1	100%

Published Standard Number 3 – Quality of Documentation

Application number	Application type	Number of applications	Performance
18	Unreturned Documents	314	96%

Published Standard Number 4 – Product Defects

Task number	Task	Number of tasks	Performance	Target Days	Average Days
19	Product Defects reports	7	100%		
	High risk <5 days	0	-		
	Low risk <10 days	7	-		

Published Standard Number 5 – Import, Export and Batch Release Schemes

Application number	Application Type	No of Apps	Performance	Target Days	Average Days
20	Applications for new pharmaceutical and Immunological products	7	100%	15/25	-
21	Applications for previously imported products	25	100%	15	-
22	All other urgent applications	34	100%	-	-
	Urgent	0		2	
	Non Urgent	34		10	
23	Instant Import Certificates	3205	-	-	-
24	Export	20	100%	10	6
25	Batch Release	161	100%	10	2.4

Published Standard Number 6 – Pharmacovigilance

Task number	Task	No.	Performance
26	Human, Animal & Environmental AERs	646	99.8%
27	PSURs	97	100%
28	Inspections	2	100%

Published Standard Number 7– Inspections

Task number	Task	No.	Performance	Target Days
29	Inspections within 3 years (GMP)	1	100%	-
	Within 5 years (GDP) of last inspection	7	Joint with above	-
30	Inspection Deficiency Reports	15	100%	30.0
31	(GMP) Certificates or (GDP) final reports sent	8	100%	90.0
32	Approval of new Feed business operators and SQP retailer sites	2	100%	45.0
33	Final inspection report to Feed business operators and SQP retailers	27	100%	30.0

Our inspection procedures enable us to extend our GMP inspections beyond 3 years and our GDP inspections beyond 5 years where there are exceptional circumstances, provided a documented risk-assessment is carried out. Risk-assessments have been conducted for all sites where it has not been possible for us to inspect them within 3 years due to covid-19 related restrictions, which were in place until March 2022.

Key:

100% Excellent

>97% - 100% Excellent, but some targets missed

92% - 97% Effective

< 91% Ineffective

Additional information

The VMD continuously monitors all targets and puts in place countermeasures, where possible, to ensure targets are met.

However, sometimes a performance standard may fall into the effective or ineffective category and there are a number of reasons why this may happen, for example high volume of applications, staff resource, complexity of applications requiring additional input and so on.